Electronic cigarettes: The nicotyrine hypothesis

Medical Hypotheses

Volumn 85, Issue 3, 2015, Pages 305-310

  Abramovitz, Aaron ^a   McQueen, Amy ^a   Martinez, Raul E ^b   Williams, Brent J ^b   Sumner, Walton ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; BILIRUBIN; CIGARETTE SMOKE; COTININE; CYTOCHROME; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; NICOTINE DERIVATIVE; NICOTYRINE; UNCLASSIFIED DRUG; VALPROIC ACID; NICOTINE;

AEROSOL; ARTICLE; BEHAVIOR CHANGE; BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ELECTRONIC CIGARETTE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; METABOLITE; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OXIDATION; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; TRACHEA MUCOSA; URINARY EXCRETION; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES;

NICOTIANA TABACUM;

ELECTRONIC CIGARETTES; HUMANS; NICOTINE; SMOKING;

EID: 84939562318     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.06.002     Document Type: Article

References (68)

1. Farsalinos K.E., Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf 2014, 5(2):67-86.
2. McQueen A., Tower S., Sumner W. Interviews with "vapers": implications for future research with electronic cigarettes. Nicotine Tob Res 2011, 13(9):860-867.
3. Etter J.F., Eissenberg T. Dependence levels in users of electronic cigarettes, nicotine gums and tobacco cigarettes. Drug Alcohol Depend 2015, 147:68-75.
4. Foulds J., Veldheer S., Yingst J., Hrabovsky S., Wilson S.J., Nichols T.T., et al. Development of a questionnaire for assessing dependence on electronic cigarettes among a large sample of ex-smoking e-cigarette users. Nicotine Tob Res 2015, 17(2):186-192.
5. Dawkins L., Turner J., Roberts A., Soar K. 'Vaping' profiles and preferences: an online survey of electronic cigarette users. Addiction 2013, 108(6):1115-1125.
6. Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control 2010, 19(1):87-88.
7. Vansickel A.R., Cobb C.O., Weaver M.F., Eissenberg T.E. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev 2010, 19(8):1945-1953.
8. Vansickel A.R., Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res 2012, 15(1):267-270.
9. Polosa R., Caponnetto P., Morjaria J.B., Papale G., Campagna D., Russo C. Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health 2011, 11:786.
10. Caponnetto P., Auditore R., Russo C., Cappello G.C., Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health 2013, 10(2):446-461.
11. Polosa R., Morjaria J.B., Caponnetto P., Campagna D., Russo C., Alamo A., et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Intern Emerg Med 2014, 9(5):537-546.
12. Caponnetto P., Campagna D., Cibella F., Morjaria J.B., Caruso M., Russo C., et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS ONE 2013, 8(6):e66317.
13. Bullen C., Howe C., Laugesen M., McRobbie H., Parag V., Williman J., et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013, 382(9905):1629-1637.
14. Steinberg M.B., Zimmermann M.H., Delnevo C.D., Lewis M.J., Shukla P., Coups E.J., et al. E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices. J Gen Intern Med 2014.
15. Cheng T. Chemical evaluation of electronic cigarettes. Tob Control 2014, 23(Suppl. 2):ii11-ii17.
16. Westenberger B. Evaluation of e-cigarettes. St. Louis, MO: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Division of Pharmaceutical Analysis; 2009.
17. Woodward C, Badgett C, Haines P: Catalytic vapor phase oxidation of nicotine to 3,2'-nicotyrine. In., vol. #US 2432642 A. United States; 1947.
18. Martinez R.E., Dhawan S., Sumner W., Williams B.J. On-line chemical composition analysis of refillable electronic cigarette aerosol-measurement of nicotine and nicotyrine. Nicotine Tob Res 2014.
19. Kramlinger V.M., von Weymarn L.B., Murphy S.E. Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, beta-nicotyrine and menthol. Chemico-biol. Interact. 2012, 197(2-3):87-92.
20. Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 2000, 60(18):5074-5079.
21. Di Y.M., Chow V.D., Yang L.P., Zhou S.F. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009, 10(7):754-780.
22. Chiang H.C., Wang C.K., Tsou T.C. Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract. Respiration 2012, 84(4):319-326.
23. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005, 57(1):79-115.
24. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996, 24(11):1212-1217.
25. Liu T., Xie C.B., Ma W.J., Chen W.Q. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. Environ Mol Mutagen 2013, 54(2):133-140.
26. Rossini A., De Almeida Simao T., Pinto L.F. CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 2008, 9(11):1737-1752.
27. Tamaki Y., Arai T., Sugimura H., Sasaki T., Honda M., Muroi Y., et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet 2011, 26(5):516-522.
28. Minematsu N., Nakamura H., Iwata M., Tateno H., Nakajima T., Takahashi S., et al. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax 2003, 58(7):623-628.
29. To Steep Or Not To Steep An eJuice. http://cerebralrift.org/2014/03/04/steep-steep-ejuice/.
30. Our Artisan E-Liquid. http://www.thesteamco.com/pages/about-our-ejuice.
31. Stalhandske T., Slanina P. Nicotyrine inhibits in vivo metabolism of nicotine without increasing its toxicity. Toxicol Appl Pharmacol 1982, 65(3):366-372.
32. Bagdas D., Muldoon P.P., Zhu A.Z., Tyndale R.F., Damaj M.I. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 2014, 85:67-72.
33. Lee B.L., Benowitz N.L., Jacob P. Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. Clin. Pharmacol Ther 1987, 41(4):474-479.
34. Denton T.T., Zhang X., Cashman J.R. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 2004, 67(4):751-756.
35. Kramlinger V.M. Characterization of beta-nicotyrine-mediated inactivation of cytochrome P450 2A6 2013, University of Minnesota.
36. Denton T.T., Zhang X., Cashman J.R. 5-Substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem 2005, 48(1):224-239.
37. Cashman JR. Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer. In: USPTO (ed.). United States: Human BioMolecular Research Institute (San Diego, CA); 2013.
38. Castagnoli N, Liu X, Shigenaga MK, Wardrop R, Castagnoli K. Studies on the metabolic fate of (S)-nicotine and its pyrrolic analog B-nicotyrine. In: Benowitz (ed.). Nicotine safety and toxicity. New York (NY): Oxford University Press; 1998: 57-65.
39. Liu X., Castagnoli K., Van Der Schyf C.J., Castagnoli N. Studies on the in vivo biotransformation of the tobacco alkaloid beta-nicotyrine. Chem Res Toxicol 2000, 13(5):336-341.
40. Farsalinos K.E., Romagna G., Voudris V. Factors associated with dual use of tobacco and electronic cigarettes: a case control study. Int J Drug Policy 2015.
41. Food and Drug Administration. In: Electronic Cigarettes and the Public Health: Second Public Workshop. Hyattsville, MD; 2015.
42. Sumner H.M., McQueen A., Scott M.J., Sumner W. Analysis of comments in a petition defending electronic cigarettes. Nicotine Tob Res 2014.
43. Fagerstrom K., Eissenberg T. Dependence on tobacco and nicotine products: a case for product-specific assessment. Nicotine Tob Res 2012, 14(11):1382-1390.
44. Zhang Z., Kleinstreuer C., Hyun S. Size-change and deposition of conventional and composite cigarette smoke particles during inhalation in a subject-specific airway model. J Aerosol Sci 2012, 46:34-52.
45. Zhao Y., Kreisberg N.M., Worton D.R., Teng A.P., Hering S.V., Goldstein A.H. Development of an in situ thermal desorption gaschromatography instrument for quantifying atmospheric semi-volatile organic compounds, aerosol science and technology. Aerosol Sci Technol 2013, 47(3):258-266.
46. French F, Freedlander B, Furst A. Absence of effect of myosmine and nicotyrine on the development of spontaneous pulmonary adenomas in strain a mice. In: Proceedings of the American Association for Cancer Research/Legacy Tobacco Documents Library. Cancer Research, Inc/University of California, San Francisco; 1957.
47. Nakajima M., Iwata K., Yamamoto T., Funae Y., Yoshida T., Kuroiwa Y. Nicotine metabolism in liver microsomes from rats with acute hepatitis or cirrhosis. Drug Metab Dispos 1998, 26(1):36-41.
48. Raunio H., Rautio A., Gullsten H., Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001, 52(4):357-363.
49. Wang H., Tan W., Hao B., Miao X., Zhou G., He F., et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003, 63(22):8057-8061.
50. Wong H.L., Zhang X., Zhang Q.Y., Gu J., Ding X., Hecht S.S., et al. Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes. Chem Res Toxicol 2005, 18(6):913-918.
51. Jalas J.R., Hecht S.S., Murphy S.E. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005, 18(2):95-110.
52. Griffin A.C. Methoxsalen in ultraviolet carcinogenesis in the mouse. J Invest Dermatol 1959, 32(2):367-372. Part 2.
53. Gu J., Su T., Chen Y., Zhang Q.Y., Ding X. Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol 2000, 165(2):158-162.
54. Maenpaa J., Rane A., Raunio H., Honkakoski P., Pelkonen O. Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse. Biochem Pharmacol 1993, 45(4):899-907.
55. Azziz-Baumgartner E., Lindblade K., Gieseker K., Rogers H.S., Kieszak S., Njapau H., et al. Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ Health Perspect 2005, 113(12):1779-1783.
56. Schwartzbord J.R., Emmanuel E., Brown D.L. Haiti's food and drinking water: a review of toxicological health risks. Clin Toxicol (Phila) 2013, 51(9):828-833.
57. Abu-Bakar A., Hakkola J., Juvonen R., Rahnasto-Rilla M., Raunio H., Lang M.A. Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver. Curr Drug Metab 2013, 14(1):137-150.
58. Abu-Bakar A., Arthur D.M., Wikman A.S., Rahnasto M., Juvonen R.O., Vepsalainen J., et al. Metabolism of bilirubin by human cytochrome P450 2A6. Toxicol Appl Pharmacol 2012, 261(1):50-58.
59. Polosa R. Electronic cigarette use and harm reversal: emerging evidence in the lung. BMC Med 2015, 13:54.
60. Watson C. Device design and design risks. In: A Public Workshop - Electronic Cigarettes and the Public Health. Silver Spring, MD: Food and Drug Administration; 2014.
61. McDonald SG. Material hazards associated with e-cigarettes. In: (CTP) CfTP (ed.). Electronic Cigarettes and the Public Health: A Public Workshop. Silver Spring, MD: Food and Drug Administration; 2014: 28-38.
62. CBS news staff. Electronic cigarette explodes in man's mouth, causes serious injuries; 2012.
63. Barrington-Trimis J.L., Samet J.M., McConnell R. Flavorings in electronic cigarettes: an unrecognized respiratory health hazard?. JAMA 2014, 312(23):2493-2494.
64. Williams M., Villarreal A., Bozhilov K., Lin S., Talbot P. Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol. PLoS ONE 2013, 8(3):e57987.
65. Hutzler C., Paschke M., Kruschinski S., Henkler F., Hahn J., Luch A. Chemical hazards present in liquids and vapors of electronic cigarettes. Arch Toxicol 2014, 88(7):1295-1308.
66. Durmowicz EL, Chen I-L, Rudy SF. Electronic cigarettes: risks to nonusers. In: AAP National Conference & Exhibition: October 12 2014; San Diego; 2014.
67. Ballbe M., Martinez-Sanchez J.M., Sureda X., Fu M., Perez-Ortuno R., Pascual J.A., et al. Cigarettes vs. e-cigarettes: passive exposure at home measured by means of airborne marker and biomarkers. Environ Res 2014, 135:76-80.
68. Polosa R., Rodu B., Caponnetto P., Maglia M., Raciti C. A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J 2013, 10:19.